Skip to main content

Advertisement

SpringerLink
Log in

Supportivtherapieleitlinie

Anämie bei Krebserkrankung

  • Supportivtherapie
  • Published:
Im Fokus Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

© H. Link

Abb. 2

H. Link

Literatur

  1. Knight K et al. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):11S-26S

  2. Link H, Schmitz S. Treatment of cancer-associated anaemia: results from a two-day cross-sectional survey in Germany. Onkologie. 2013 36(5):266-72

  3. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23

  4. Miller CB et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322(24):1689-92

  5. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117:4425-33

  6. Ganz T. Anemia of Inflammation. N Engl J Med. 2019;381(12):1148-57

  7. Katodritou E et al. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol. 2007;86:369-76

  8. Auerbach M et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004;22(7):1301-7

  9. Bovy C et al. Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity. Nephrol Dial Transplant. 2007;22(4):1156-62

  10. Littlewood TJ et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-74

  11. Witzig TE et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005;23(12):2606-17

  12. Querschnitts-Leitlinien BAEK zur Therapie mit Blutkomponenten und Plasmaderivaten-Gesamtnovelle 2020. Berlin: Bundesärztekammer; 2020.

  13. Funk MB et al. Hämovigilanz-Bericht des Paul-Ehrlich-Instituts 2019: Auswertung der Meldungen von Reaktionen und Zwischenfällen nach § 63i AMG. 2021

  14. Szczepiorkowski ZM, Dunbar NM. Transfusion guidelines: when to transfuse. ASH Educ Program Book. 2013;2013(1):638-44

  15. Hicks LK et al. The ASH Choosing Wisely(R) campaign: five hematologic tests and treatments to question. Blood. 2013;122(24):3879-83

  16. Gross I et al. Critical role of iron in epoetin alfa treatment of chemotherapy-associated anemia. J Clin Oncol. 2016;https://doi.org/10.1200/jco.2016.67.7377

  17. Musallam KM et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet. 2011;378(9800):1396-1407

  18. Hebert PC et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409-17

  19. Villanueva C et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368:11-21

  20. Tomic Mahecic T et al. RBC transfusion triggers: is there anything new? Transfus Med Hemother. 2020;47(5):361-9

  21. Carson JL et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016; 10(10):CD002042

  22. Carson JL et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011;365:2453-62

  23. Salpeter SR et al. Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review. Am J Med. 2014;127(2):124-31.e3

  24. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;https://doi.org/10.1002/14651858.CD005033.pub2

  25. Mortensen FV, Jensen LS, Sörensen HT, Pedersen L. Cause-specific mortality associated with leukoreduced, buffy coat-depleted, or no blood transfusion after elective surgery for colorectal cancer: a posttrial 15-year follow-up study. Transfusion. 2011;51:259-63

  26. Tillo JJ et al. Association between red blood cell transfusions and development of non-hodgkin lymphoma: a meta-analysis of observational studies. Blood. 2010;116:2897-907

  27. Meybohm PZ. Kai: patient blood managment. 2021;https://www.patientbloodmanagement.de/. Zugegriffen: 27. Nov. 2021

  28. Leahy MF et al. Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. Transfusion. 2017;57(6):1347-58

  29. Aapro M et al. Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv96-iv110

  30. Supportive Therapie bei onkologischen PatientInnen - Langversion 1.0, 2016, AWMF Registernummer: 032/054OL. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Berlin: DKG, ASORS, DGHO, DEGRO. Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF), Deutschen Krebsgesellschaft e. V. (DKG) und Deutschen Krebshilfe (DKH); 2016. http://leitlinienprogramm-onkologie.de/Supportive-Therapie.95.0.html

  31. Bohlius J et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol. 2019;37(15):1336-51

  32. Tonia T et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;https://doi.org/10.1002/14651858.CD003407.pub5

  33. Goodnough LT et al. Erythropoietin, iron, and erythropoiesis. Blood. 2000;96(3):823-33

  34. Bastit L et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26:1611-8

  35. Steensma DP et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 2011;29:97-105

  36. Aapro M et al. Too-low iron doses and too many dropouts in negative iron trial? J Clin Oncol. 2011;29(17):e525-e526

  37. Gafter-Gvili A et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia—systematic review and meta-analysis of randomised controlled trials. Acta Oncol. 2013;52(1):18-29

Download references

Author information

Authors and Affiliations

  1. Abtlg. Hämatologie u. Onkologie, Westpfalz-Klinikum, Med. Klinik I, Hellmut-Hartert-Str. 1, 67655, Kaiserslautern, Deutschland

    Hartmut Link

Authors

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Link, H. Anämie bei Krebserkrankung. Im Fokus Onkologie 25, 46–50 (2022). https://doi.org/10.1007/s15015-022-3904-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-022-3904-1

Search

Navigation